Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022

Rhea-AI Summary

Sonoma Pharmaceuticals, Inc. (SNOA) announces its participation in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Amy Trombly and CFO Jerry Dvonch will present the company's business overview. Institutional investors can register for the virtual event through the provided link. Sonoma specializes in developing stabilized hypochlorous acid (HOCl) products for various healthcare applications, reducing infections and promoting healing. The company operates globally, distributing products in 54 countries.

WOODSTOCK, Ga.--(BUSINESS WIRE)-- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference. The conference is being held on January 10-13, 2022 virtually.

Amy Trombly, CEO and Jerry Dvonch, CFO will provide an overview of the Company’s business during the presentation.

If you are an institutional investor, and would like to listen to the Company’s presentation, please click on the following link (www.hcwevents.com/bioconnect) to register for the conference. Over 500 corporate presentations & panels are available on-demand during January 10-13, 2022.

Event: H.C. Wainwright BioConnect Conference (Virtual Conference)
Date: January 10-13, 2022
Location: Virtual Conference

In addition, the Company will furnish the presentation on a current report on Form 8-K with the U.S. Securities and Exchange Commission via EDGAR.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “believe,” “develop” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105006001/en/

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.

ir@sonomapharma.com

Source: Sonoma Pharmaceuticals, Inc.

FAQ

When is Sonoma Pharmaceuticals presenting at the H.C. Wainwright BioConnect Conference?

Sonoma Pharmaceuticals will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022.

Who will represent Sonoma Pharmaceuticals at the conference?

CEO Amy Trombly and CFO Jerry Dvonch will represent Sonoma Pharmaceuticals at the conference.

What products does Sonoma Pharmaceuticals develop?

Sonoma Pharmaceuticals develops stabilized hypochlorous acid (HOCl) products for wound care, eye care, nasal care, oral care, and dermatological conditions.

How can institutional investors register for the H.C. Wainwright BioConnect Conference?

Institutional investors can register for the conference through the link provided in the press release.

In how many countries does Sonoma Pharmaceuticals distribute its products?

Sonoma Pharmaceuticals distributes its products in 54 countries worldwide.